Conclusions: This study demonstrates a paradigm shift in the treatment of primary mycotic abdominal aortic aneurysms (MAAAs) in Sweden to the use of endovascular aneurysm repair (EVAR) as the preferred modality. EVAR was associated with improved short-term survival in comparison to open repair and without a higher incidence of serious infectious complications or reoperations.
Conclusions: This study demonstrates a paradigm shift in the treatment of primary mycotic abdominal aortic aneurysms (MAAAs) in Sweden to the use of endovascular aneurysm repair (EVAR) as the preferred modality. EVAR was associated with improved short-term survival in comparison to open repair and without a higher incidence of serious infectious complications or reoperations.
Summary: This retrospective study of a prospectively collected nationwide database spanned 10 years . All patients treated for a primary MAAAs were identified in the Swedish vascular registry (Swedvasc) . The primary aim was assessment of survival after open repair (OR) or EVAR of a MAAA. Secondary end points were analysis of the rate of recurrent infections and reoperations as well as the time trends in surgical treatment. Propensity score-weighted correction for risk factors in the 2 groups was performed including the operative year to account for differences in treatment and outcome over time. One hundred and thirty-two patients were identified (0.6% of all AAA repairs) with mean age of 70. Rupture was the presenting symptom in 50 patients. Overall survival was 86% at 3 months, 79% at 1 year, and 59% at 5 years. The treatment modality shifted over this study, EVAR was not used prior to 2001 (n ¼ 14 repairs), jumped to 58% during 2001-2007 (n ¼ 43 repairs) , and was used 60% of the time during 2008-2014 (n ¼ 75 repairs). Eight patients had multiple aortic aneurysms defined as a combination of infrarenal, paravisceral, and/or thoracic. The most common infectious agents were Streptococcus (22%), Staphlococcus (16%), and Salmonella (9%). Of the 62 patients treated with open repair, 50 were in situ reconstructions, 7 aortic resections and extra-anatomic bypasses, and 3 patch angioplasties. Two patients died intraoperatively. There were 70 EVAR repairs (55 standard, 8 fenestrated/ branched, and 7 visceral deviation and stent graft and without an interventional death). Antibiotics were administered for a median of 12 weeks (OR, and EVAR, 16 weeks ). Eight had percutaneous drainage (2 OR, 6 EVAR). Survival at 3 months was lower for OR than EVAR (74% vs 96%; P < .001), with a like trend at 1 year (73% vs 84%; P ¼ .54). Ruptured MAAAs had a higher mortality (74%) than intact MAAA repairs (93%; P ¼ .003). Twenty-eight patients experienced an infectionrelated complication (21%) of which 46% were fatal but no association could be found between the presence of positive blood cultures, bacterial species present, or duration of antibiotic use. The median time until infection-related complication was 3 months and 75% occurred within the first year after surgery. The propensity score-weighted risk-adjusted analysis confirmed better early survival with EVAR. At five years comparing OR to EVAR, there was no difference in long-term survival (60% vs 58%; P ¼ .77), infection-related complications (18% vs 24%; P ¼ .44) and reoperation (21% vs 24%; P ¼ .65).
Comments: It should be clarified that the patients presented in this study are primary aortic infections presenting as aneurysmal disease and signs/symptoms/finding of infection. It is the currently largest such series in the literature. Excluded are primary aortoenteric fistula, inflammatory aneurysms, graft infections, graft-enteric fistulas and those with prior aortic surgery. The data do not allow a determination of preinterventional antibiotics use or duration. It does not have the detail to provide patient factors which might favor the recommendation of one approach over the other. However, it does provide data to suggest that EVAR can be a durable treatment of primary aortic infection; a viable option in the elderly, those in shock or immunosuppressed who otherwise might not be consider candidates for intervention; and, in a few (four cases in this series) a bridge to open surgery.
Systematic Review and Meta-Analysis of Dual Versus Single Antiplatelet Therapy in Carotid Interventions
Barkat M, Hajibandeh S, Hajibandeh S, Torella F, Antoniou GA. Eur J Vasc Endovasc Surg 2017;53:53-68.
Conclusions: Dual antiplatelet therapy demonstrates advantages over single therapy only in patients treated with a carotid artery stent as determined by a decrease risk of transient ischemia attack. Dual therapy was associated with an increased risk of major bleeding, neck hematoma and MI in those undergoing carotid endarterectomy with no benefit regarding protection from transient ischemic attack (TIA)/stroke/ mortality.
Summary: Electronic information sources and bibliographic reference lists were searched to identify randomized controlled trials and observational studies reporting comparative outcomes of dual versus single antiplatelet therapy in CEA and CAS. Both asymptomatic and symptomatic patients were included of any age and gender but excluding those within 14 days of thrombolysis given for the management of acute stroke. Primary outcomes were 30 day mortality and stroke. Secondary outcomes were TIA, major bleeding, groin or neck hematoma and MI. Initial search found 1172 articles; 1128 were not relevant, comparative or were systemic reviews; 18 were duplicates; 5 were added from references but another 12 excluded for lack of primary outcome, had no carotid intervention or were not comparing dual verses single antiplatelet agent. The remaining were three randomized controlled trials (RCTs) and seven observational studies. One RCT and seven retrospective observational studies reporting a total of 36,881 CEAs, of which 8536 were in the dual therapy and 27,320 in the single-agent treatment group and 1101 received no antiplatelet therapy. Aspirin and clopidogrel were the antiplatelet treatment in all studies. Demographic and clinical characteristics were not statistically different between single and dual treatment groups. Symptomatic patient outcomes were available in 6 studies and 3 studies provide dual antiplatelet therapy mainly for symptomatic patients. Only two studies reported the type of postoperative stroke of which only one was hemorrhagic. There was no difference in stroke (0.91% vs 0.79%), TIA (1.30% vs 1.12%) or 30-day mortality (0.21% vs 0.25%) between single and dual therapy. There was a significant increased risk of major bleeding (0.83% vs 1.27%: RD, 0.00; 95% confidence interval [CI], 0.00-0.01; P ¼ .0003), neck hematoma (6.77% vs 8.19%: RD, 0.04; 95% CI, 0.01-0.06; P ¼ .001) and rate of MI (1.11% vs 0.73%: RD, 0.00; 95% CI, 0.00-0.01; P ¼ .003). when using dual therapy. The Grade of evidence was estimated as low for all analyses. Statistical heterogeneity was general low or not present. Two RCTs evaluated dual versus single therapy in 150 CAS procedures, 75 in each group. Acetylsalicylic acid, clopidogrel, and ticlopidine were the agents used and in both trials patients in the single therapy group were provided heparin infusion for 24 hours postintervention as well. There was no demographic or clinical characteristics difference between groups and both provided data on symptomatic patients. One study provided information on the type of stroke postintervention and no hemorrhagic strokes were reported. In CAS single versus dual therapy, the was no statistical difference in mortality (0% vs 1.3%), stroke (4% vs 0%), MI (0% in each), major bleeding (0% in each) or groin hematoma (8% vs 4%) but a significant difference was identified in the risk of TIA in favor of dual therapy (14.6% vs 1.3%: RD, À0.13; 95% CI, À0.22 to À0.05; P ¼ .003). The grade of evidence was estimated as moderate for all analyses with no statistical heterogeneity. The dual agent in 2/3 rd of the patients was ticlopidine in addition to acetylsalicylic acid.
Comments: This study does support the use of dual therapy post-CAS to decrease the risk of TIA. The small number of patients in the analyses introduces a potential statistical bias and the majority of patients were treated with a drug (ticlopidine) removed from the market. For CEA, dual therapy provides no neurologic protection but does add bleeding and potentially a worse MI outcome. The study does not provide information on platelet function which can be an issue with clopidogrel nonresponders. It is apparent from the authors' discussion of study limitations and grade of evidence that the final word regarding dual therapy use postcarotid intervention is yet to be determined.
Endovascular Treatment of Hepatic Artery Pseudoaneurysm After Pancreaticoduodenectomy: Risk Factors Associated With Mortality and Complications
Hasegava T, Ota H, Matsuura T, Seiji K, Mugikura S, Motoi F, et al. J Vasc Interv Radiol 2017; 28:50-9. Conclusions: Hemorrhagic shock and coagulopathy are correlated with a poor early prognosis suggesting that early intervention prior to these events may improve survival. Coagulopathy prior to intervention, portal vein stenosis and lack of hepatic arterial flow through hepatic arteries after intervention correlates with major hepatic complications suggesting that these factors are important to hepatic health.
Summary: This study investigates the risks factors which might lead to death or hepatic failure postpancreatectomy who required endovascular treatment to treat hemorrhage or pseudoaneurysm. Forty patients were found but 12 were eliminated from analysis since the hepatic artery was not treated. This left 28 patients with intervention required of the common hepatic artery or its distal arteries. The diagnosis was clinical (n ¼ 26), noted as blood in the abdominal drain or NG tube (n ¼ 19), hemorrhagic shock (n ¼ 8), and hematemesis and/or melena in six patients. In 20 of these 21 patients, hemorrhage and/or pseudoaneurysm were apparent on computed tomography (CT) imaging. Two patients did not have an imminent clinical bleeding issues but imaging noted a pseudoaneurysm in fluid collections and with irregular shapes concerning for rupture. Eight patients had a platelet count <50K and/or international normalized ratio >1.5. CT imaging was used to determine a replaced hepatic artery and significant portal vein stenosis (>50% on portal-phase imaging). In five patients, arterial and portal venous findings were based on angiography since CT was not available. Four or 5-F sheath were used for diagnostic imaging, hemorrhage or pseudoaneurysms found in the common hepatic artery or gastroduodenal stump with no replaced hepatic artery were treated with either stent or perfusion catheters to preserve hepatopetal flow via hepatic arteries. Stents were a self-expanding covered metallic stent to cover the lesion or bare-metal stent with coil embolization through the stent into the bleeding site. Alternatively, a perfusion catheter was placed to perfuse the hepatic artery and a coaxial catheter used microcoils to embolize the bleeding site. In patients with a replaced hepatic artery, coil embolization with or without n-butyl cyanoacrylate injection into the common hepatic artery was performed with expectation of collateral flow providing adequate liver perfusion through the replaced hepatic through communicating arcades. Post intervention angiography confirmed the absence of bleeding and maintenance of at least one hepatic artery flow directly or via collaterals. Maximal duration of follow-up was one year with follow-up until death or LTF but few specifics are provided. Hepatic failure was a major complications and present if liver enzymes were $ 1000 U/L or gradually increase > 10 mg/dL within 7 days. Hepatic abscess was a CT diagnosis in addition to inflammatory markers. Recurrent bleeding and the need for additional interventions were also assessed. The majority of bleeding was from the common hepatic or GDA stump (n ¼ 19) or proper hepatic artery (n ¼ 4), right hepatic (n ¼ 3) and left hepatic artery (n ¼ 2). Portal vein stenosis was noted in 57%. A covered stent was used in 1 case, bare-metal with embolization in 5 cases, perfusion catheter assisted embolization in 5, and coil embolization in 17. Technical success was 100%. Hepatopedal arterial flow was noted in 93% via collaterals and 64 direct flow. Major hepatic complications were noted in 9 cases; 7 hepatic failures, 4 abscess and 2 both. Repeat bleeding requiring endovascular therapy (EVT) occurred in 7 cases with a second episode in 3 at the same site and 4 at a different site. Seventy-one percent were alive at discharge, mortality was 29% and interval to death was a median of 25.5 months. Long-term data is not specifically provided nor is data provided in a life-table method. Hemorrhagic shock (n ¼ 8: 2 alive/6 deceased; P ¼ .0018) and coagulopathy (n ¼ 8: 2 alive/6 deceased; P ¼ .0018) at onset were significantly associated with death prior to discharge. Portal vein stenosis, lack of hepatopetal flow, or repeat procedures (4 alive/3 deceased) did not statistically effect discharge mortality. Overall, eight patients had coagulopathy (two did not experience hepatic failure and survived, while six experienced hepatic failure and died; P ¼ .003 in multivariant analysis), and 10 patients demonstrated a lack of visualization of hepatopetal arterial flow through hepatic arteries (P ¼ .01, multivariant analysis); both were statistically associated with major hepatic complications. The presence of portal vein stenosis noted in 16 patients also were associated with major hepatic complications (P ¼ .03).
Comments: This study suggests that shock and coagulopathy prior to intervention to stop a bleeding event postpancreatectomy are associated with increased mortality. This may be expected based on what we know from the general trauma literature. Those factors associated with major hepatic eventsereduced blood supply from direct arterial flow and reduced portal blood floweare also intuitive since both would decrease liver perfusion. Unfortunately, the study can only suggest that these factors are important since the small numbers and extensive statistical analyses provide for significant statistical error which may or may not be clinically significant end points. The technical variations are too numerous to provide sufficient data to determine which technique performs better. There is essentially no long-term clinical follow-up provided, so little can be determined with regard to long-term success using these techniques. Only variables that could easily be collected preoperatively were recorded and used for analysis. It was specifically stated that the 30-day hospital mortality was available in the database. Variables were entered into a multivariable logistic regression model to identify independent predictors of 30-day mortality. Linear regression analysis was then undertaken to determine an equation to predict risk of 30-day mortality. Six hundred and forty-nine patients underwent rAAA repair, of which 247 were treated by endovascular aneurysm repair (EVAR) (38.1%) and 402 with open repair (61.9%). The overall mortality was 30.7% (33.4% open, 26.2% EVAR). Multivariate modeling demonstrated that the primary determinants of 30-day mortality were advanced age (>76 vs #76 years old; odds ratio [OR], 2.91), elevated serum creatinine (>1.5 vs #1.5 mg/dL; OR, 1.57), and lowest reported systolic blood pressure (BP <70 vs >70 mm Hg; OR, 2.65). The linear regression model (C-statistic of 0.69) determined a % 30-day mortality ¼ 14 + 22 (age >76 years) + 9 (creatinine >1.5 mg/dL) + 20 (BP <70 mm Hg). Using this model, patients can be stratified into specific estimated 30-day mortality risk groups from a low of 14% to a high of 65%.
Predicting Mortality of Ruptured
Comments: For the elderly patient with renal insufficiency presenting in shock, a high 30-day mortality with associated morbidity may change the decision for aggressive intervention and/or transfer to a regional center for care. This study includes both open and EVAR cases; the latter were not included in prior models to determine rAAA mortality risk and so this model is more applicable to our modern approach to the care for these patients. Conclusions: In pseudoxanthoma elasticum (PXE), a vascular phenotype can be identified with a distribution of arterial calcifications that is distinct from hospital controls and involves arterial calcifications in the legs, intracranial internal carotid arteries, and arteries of the arms.
Summary: PXE is a rare monogenetic disease caused by mutations in the ABCC6 gene that leads to calcification of the skin, the eyes, and the arterial walls. This mutation results in inefficient mediators of ATP secretion in the liver, resulting in low levels of inorganic pyrophosphate with progressive ectopic calcifications. It is currently not known how arterial calcifications are distributed in the body and how the distribution is different from control patients. In this study, 104 PXE patients from the Dutch PXE cohort were compared to 93 hospital controls (scans obtained for melanoma staging, fever of unknown origin, or suspicion of malignancy). All patients underwent low-dose (<3 mSv) full-body computed tomography without contrast to determine prevalence and severity of arterial calcifications per arterial location. The computed tomography scans were scored on a reproducible semiquantitative scale with four calcification categories. PXE patients (38/104 males) were 54 6 13 years old and controls (45/93 males) were 54 6 16 years old, with statistically lower incidence of renal failure (0% vs 7%) and higher blood pressure (137/80 vs 130/76) in those with PXE. Arterial calcifications were
